Hunan University of Chinese Medicine, Changsha, 410208, China.
Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Purinergic Signal. 2023 Mar;19(1):265-272. doi: 10.1007/s11302-021-09839-x. Epub 2022 Jan 3.
Atherosclerosis is the main pathological basis of cardiovascular disease and involves damage to vascular endothelial cells (ECs) that results in endothelial dysfunction (ED). The vascular endothelium is the key to maintaining blood vessel health and homeostasis. ED is a complex pathological process involving inflammation, shear stress, vascular tone, adhesion of leukocytes to ECs, and platelet aggregation. The activation of P2X4, P2X7, and P2Y2 receptors regulates vascular tone in response to shear stress, while activation of the A2A, P2X4, P2X7, P2Y1, P2Y2, P2Y6, and P2Y12 receptors promotes the secretion of inflammatory cytokines. Finally, P2X1, P2Y1, and P2Y12 receptor activation regulates platelet activity. These purinergic receptors mediate ED and participate in atherosclerosis. In short, P2X4, P2X7, P2Y1, and P2Y12 receptors are potential therapeutic targets for atherosclerosis.
动脉粥样硬化是心血管疾病的主要病理学基础,涉及血管内皮细胞(EC)的损伤,导致内皮功能障碍(ED)。血管内皮是维持血管健康和内稳态的关键。ED 是一个涉及炎症、切应力、血管张力、白细胞与 EC 黏附以及血小板聚集的复杂病理过程。P2X4、P2X7 和 P2Y2 受体的激活调节了对切应力的血管张力,而 A2A、P2X4、P2X7、P2Y1、P2Y2、P2Y6 和 P2Y12 受体的激活促进了炎症细胞因子的分泌。最后,P2X1、P2Y1 和 P2Y12 受体的激活调节血小板活性。这些嘌呤能受体介导 ED 并参与动脉粥样硬化。总之,P2X4、P2X7、P2Y1 和 P2Y12 受体是动脉粥样硬化的潜在治疗靶点。
Purinergic Signal. 2023-3
J Thromb Haemost. 2003-2
Arterioscler Thromb Vasc Biol. 2015-9-10
J Cardiovasc Pharmacol. 2002-12
Am J Physiol Regul Integr Comp Physiol. 2006-5
Am J Physiol Cell Physiol. 2010-10-20
Front Biosci. 2006-5-1
J Physiol Biochem. 2025-7-16
Int J Mol Sci. 2025-2-27
Purinergic Signal. 2025-3-12
Front Physiol. 2024-8-20
Naunyn Schmiedebergs Arch Pharmacol. 2025-2
Int J Mol Sci. 2024-2-6
Biology (Basel). 2024-1-26
Purinergic Signal. 2025-2
Front Immunol. 2023
Int J Mol Sci. 2023-8-30
Purinergic Signal. 2021-3
Purinergic Signal. 2021-3
N Engl J Med. 2020-7-16
J Mol Cell Cardiol. 2020-2-11